Impel Pharmaceuticals
Updated: May 20, 2026
Michael Hite - Co-Founder & CEO
Country: USA | Funding: $261.3M (+)
Founded: 2008
Website: https://impelpharma.com/
Impel Pharmaceuticals has created FDA-approved nasal spray Trudhesa for the relief of acute migraine attacks with or without aura in adults. Trudhesa gently delivers dihydroergotamine mesylate - therapeutic agent, quickly into the bloodstream through the vascularized upper nasal space. It bypasses the intestines and potential absorption issues, providing rapid, long-lasting, and consistent relief. Impel also developed its proprietary Precision Olfactory Delivery drug delivery technology, which targets the vascularized upper nasal space. Its clinical studies have demonstrated rapid absorption and consistent bioavailability, as well as ease of use for patients, physicians, and caregivers.
Founded: 2008
Website: https://impelpharma.com/
Impel Pharmaceuticals has created FDA-approved nasal spray Trudhesa for the relief of acute migraine attacks with or without aura in adults. Trudhesa gently delivers dihydroergotamine mesylate - therapeutic agent, quickly into the bloodstream through the vascularized upper nasal space. It bypasses the intestines and potential absorption issues, providing rapid, long-lasting, and consistent relief. Impel also developed its proprietary Precision Olfactory Delivery drug delivery technology, which targets the vascularized upper nasal space. Its clinical studies have demonstrated rapid absorption and consistent bioavailability, as well as ease of use for patients, physicians, and caregivers.
